WO2008093246A3 - Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis - Google Patents

Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis Download PDF

Info

Publication number
WO2008093246A3
WO2008093246A3 PCT/IB2008/001271 IB2008001271W WO2008093246A3 WO 2008093246 A3 WO2008093246 A3 WO 2008093246A3 IB 2008001271 W IB2008001271 W IB 2008001271W WO 2008093246 A3 WO2008093246 A3 WO 2008093246A3
Authority
WO
WIPO (PCT)
Prior art keywords
arteriosclerosis
organ transplant
alloimmunity
receptor antagonist
vegf receptor
Prior art date
Application number
PCT/IB2008/001271
Other languages
French (fr)
Other versions
WO2008093246A2 (en
Inventor
Kari Alitato
Karl B Lemstroem
Antti I Nykanen
Original Assignee
Vegenics Ltd
Kari Alitato
Karl B Lemstroem
Antti I Nykanen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vegenics Ltd, Kari Alitato, Karl B Lemstroem, Antti I Nykanen filed Critical Vegenics Ltd
Priority to EP08750999.8A priority Critical patent/EP2125895B1/en
Publication of WO2008093246A2 publication Critical patent/WO2008093246A2/en
Publication of WO2008093246A3 publication Critical patent/WO2008093246A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.
PCT/IB2008/001271 2007-02-02 2008-02-01 Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis WO2008093246A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08750999.8A EP2125895B1 (en) 2007-02-02 2008-02-01 Vegf receptor antagonists for treating organ transplant alloimmunity and arteriosclerosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88806707P 2007-02-02 2007-02-02
US60/888,067 2007-02-02
US88830507P 2007-02-05 2007-02-05
US60/888,305 2007-02-05

Publications (2)

Publication Number Publication Date
WO2008093246A2 WO2008093246A2 (en) 2008-08-07
WO2008093246A3 true WO2008093246A3 (en) 2008-12-18

Family

ID=39674573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/001271 WO2008093246A2 (en) 2007-02-02 2008-02-01 Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis

Country Status (3)

Country Link
US (4) US9073997B2 (en)
EP (1) EP2125895B1 (en)
WO (1) WO2008093246A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
WO2012122374A2 (en) * 2011-03-08 2012-09-13 Children's Medical Center Corporation Non-invasive methods for diagnosing chronic organ transplant rejection
US9364535B2 (en) * 2012-08-15 2016-06-14 The Regents Of The University Of California Methods and compositions for modulating lymphangiogenesis, e.g., to treat transplant rejection, in a subject
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447095A1 (en) * 2001-11-02 2004-08-18 Kensuke Egashira Preventives and/or remedies for post-transplant arteriosclerosis as rejection of organ transplant
WO2004106378A2 (en) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
WO2005041877A2 (en) * 2003-10-29 2005-05-12 Children's Medical Center Corporation Method of inhibiting rejection following organ transplantation

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2854439A1 (en) * 1978-12-16 1980-07-03 Hoechst Ag AN ISOXAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, AGENT AND USE THEREOF
US6043211A (en) * 1988-02-02 2000-03-28 The Regents Of The University Of California Method for inhibiting the activity of a platelet-derived growth factor receptor binding protein
US5468468A (en) * 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
JPH06503966A (en) * 1990-12-21 1994-05-12 クリエイティブ　バイオモレキュルズ　インコーポレイテッド Biosynthesized PDGF antagonist
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US5620687A (en) * 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
ATE326484T1 (en) 1994-06-09 2006-06-15 Licensing Oy MONOCLONAL ANTIBODY AGAINST FLT4 RECEPTOR TYROSINE KINASE AND ITS USE FOR DIAGNOSIS AND THERAPY
US6403088B1 (en) * 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US7423125B2 (en) * 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
ES2202469T5 (en) * 1995-09-08 2011-06-06 Genentech, Inc. PROTEIN RELATED TO VEGF.
ES2341864T3 (en) * 1995-09-29 2010-06-29 Universita Degli Studi Di Siena REGULATED GENES AND USES OF THE SAME.
WO1997032604A1 (en) 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
ES2251740T3 (en) 1996-08-23 2006-05-01 Ludwig Institute For Cancer Research GROWTH FACTOR OF VASCULAR D RECOMBINANT ENDOTHELIAL CELLS (VEGF-D).
DE19638745C2 (en) * 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
CA2266419A1 (en) * 1996-09-24 1998-04-02 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
US6986890B1 (en) * 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
WO1998031794A1 (en) * 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Vegf-binding polypeptide
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
US5932580A (en) * 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
EP1105136B1 (en) 1998-08-13 2007-08-29 Novartis AG Method for treating ocular neovascular diseases
FR2785044B1 (en) 1998-10-27 2001-01-26 Gemplus Card Int UNIVERSAL TEMPLATE FOR GEOMETRIC CHECKING OF A CARD
GB9824579D0 (en) * 1998-11-10 1999-01-06 Novartis Ag Organic compounds
PT1140175E (en) * 1998-12-21 2006-06-30 Ludwig Inst Cancer Res ANTIBODIES FOR VEGF-D TRUNCATED AND ITS UTILIZATIONS
JP4876239B2 (en) 1999-01-11 2012-02-15 プリンストン ユニバーシティー High affinity inhibitors for target confirmation and use thereof
KR100816572B1 (en) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Anti-VEGF antibody and a pharmaceutical composition comprising the same
US6921763B2 (en) * 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6358954B1 (en) * 1999-11-09 2002-03-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same
EP1244672B1 (en) * 1999-12-21 2005-07-20 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
EP1248642A4 (en) * 2000-01-18 2005-05-18 Ludwig Inst Cancer Res Vegf-d/vegf-c/vegf peptidomimetic inhibitor
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
AU2001291019A1 (en) * 2000-09-15 2002-03-26 Genvec, Inc. Method of modulating neovascularization
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CN1494552A (en) * 2001-01-19 2004-05-05 ·��ά��֢�о�Ժ Flt 4 (VEGFR-3) as target for tumor imaging and anti-tumor therapy
US7402312B2 (en) * 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
EP1385862A4 (en) * 2001-04-13 2005-03-02 Human Genome Sciences Inc Vascular endothelial growth factor 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
CN1555488A (en) * 2001-07-12 2004-12-15 路德维格癌症研究院 Lymphatic endothelial cells materials and methods
WO2003020906A2 (en) * 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
US6734017B2 (en) * 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
US20030113324A1 (en) 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
CN1615137A (en) * 2002-01-10 2005-05-11 诺瓦提斯公司 Drug delivery systems for the prevention and treatment of vascular diseases comprising rapamycin and derivatives thereof
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
US20030232437A1 (en) * 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-C expression
US7479270B2 (en) 2002-07-23 2009-01-20 Vegenics Limited Methods and compositions for activating VEGF-D and VEGF-C
WO2005049021A1 (en) 2003-11-03 2005-06-02 Oy Helsinki Transplantation R & D Ltd Materials and methods for inhibiting neointimal hyperplasia
WO2005087177A2 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
DE602005027673D1 (en) * 2004-03-05 2011-06-09 Vegenics Pty Ltd MATERIALS AND METHODS FOR GROWTH FACTORY BONDING CONSTRUCTS
WO2005087812A1 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
US20060110364A1 (en) * 2004-08-20 2006-05-25 Ludwig Institute For Cancer Research Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
WO2008093246A2 (en) 2007-02-02 2008-08-07 Vegenics Limited Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447095A1 (en) * 2001-11-02 2004-08-18 Kensuke Egashira Preventives and/or remedies for post-transplant arteriosclerosis as rejection of organ transplant
WO2004106378A2 (en) * 2003-05-28 2004-12-09 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
WO2005041877A2 (en) * 2003-10-29 2005-05-12 Children's Medical Center Corporation Method of inhibiting rejection following organ transplantation

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CURSIEFEN CLAUS ET AL: "Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE JUL 2002, vol. 43, no. 7, July 2002 (2002-07-01), pages 2127 - 2135, XP002499466, ISSN: 0146-0404 *
CURSIEFEN CLAUS ET AL: "Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling.", THE AMERICAN JOURNAL OF PATHOLOGY MAY 2005, vol. 166, no. 5, May 2005 (2005-05-01), pages 1367 - 1377, XP002499465, ISSN: 0002-9440 *
DI CARLO E ET AL: "Quilty effect has the features of lymphoid neogenesis and shares CXCL13-CXCR5 pathway with recurrent acute cardiac rejections.", AMERICAN JOURNAL OF TRANSPLANTATION : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF TRANSPLANTATION AND THE AMERICAN SOCIETY OF TRANSPLANT SURGEONS JAN 2007, vol. 7, no. 1, January 2007 (2007-01-01), pages 201 - 210, XP002499464, ISSN: 1600-6135 *
RINTALA S E ET AL: "Vascular endothelial growth factor (VEGF) ligand and receptor induction in rat renal allograft rejection.", TRANSPLANTATION PROCEEDINGS DEC 2006, vol. 38, no. 10, December 2006 (2006-12-01), pages 3236 - 3238, XP002499463, ISSN: 0041-1345 *
SHO MASAYUKI ET AL: "Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo.", TRANSPLANTATION 27 SEP 2005, vol. 80, no. 6, 27 September 2005 (2005-09-27), pages 717 - 722, XP008097502, ISSN: 0041-1337 *

Also Published As

Publication number Publication date
WO2008093246A2 (en) 2008-08-07
US9896499B2 (en) 2018-02-20
US20210395339A1 (en) 2021-12-23
US9073997B2 (en) 2015-07-07
EP2125895A2 (en) 2009-12-02
US20150218249A1 (en) 2015-08-06
EP2125895B1 (en) 2015-04-08
US20080267956A1 (en) 2008-10-30
US20180118804A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
WO2008093246A3 (en) Vegf receptor antagonist for treating organ transplant alloimmunity and arteriosclerosis
WO2005087808A3 (en) Growth factor binding constructs materials and methods
HK1167325A1 (en) Antibodies against vascular endothelial growth factor receptor-1 -1
WO2011090648A3 (en) Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
PT2547679E (en) 2,3 dihydro-1h-inden-1-yl-2,7-diazaspiro[3.6]nonane derivatives and their use as antagonists or inverse agonists of the ghrelin receptor
WO2007143351A3 (en) Implantable medical endoprostheses
EP1699484A4 (en) Humanized antibodies against vascular endothelial growth factor
ATE433764T1 (en) MULTI-LAYER COMPOSITE VASCULAR PROSTHESIS
WO2012116135A3 (en) Noggin blocking compositions for ossification and methods related thereto
IL182335A0 (en) Nicotinamiide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors
WO2005072417A3 (en) Vascular endothelial growth factors and methods of their use
WO2012116137A3 (en) Jab1 blocking compositions for ossification and methods related thereto
WO2009031295A1 (en) Stent for controlled drug release
WO2011123785A3 (en) Frizzled-binding agents and uses thereof
RS54587B1 (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
WO2006124365A3 (en) Endothelial cell binding coatings for rapid encapsulation of bioerodable stents
WO2006083991A3 (en) Fiber-reinforced composite absorbable endoureteral stent
MY151191A (en) Novel antibodies
WO2010028254A3 (en) Substituted quinazoline inhibitors of growth factor receptor tyrosine kinases
HUE042434T2 (en) Monoclonal antibody for antagonizing and inhibiting binding of vascular endothelial cell growth factor and its receptor, and coding sequence and use thereof
IL198365A0 (en) Surgical implant composite materials, kits containing the same and methods of producing the same
WO2012103360A3 (en) Wnt compositions and methods of use thereof
EP1757296A4 (en) Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation
WO2007147026A3 (en) Ccr2 antagonists for chronic organ transplantation rejection

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008750999

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08750999

Country of ref document: EP

Kind code of ref document: A2